The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide.
 
Siyuan S Guo
No Relationships to Disclose
 
Susan Halabi
Employment - ASCO
Honoraria - AVEO; Bristol-Myers Squibb; Janssen; Sanofi
 
David M. Nanus
Consulting or Advisory Role - AstraZeneca; Janssen Scientific Affairs
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Exelixis (Inst); immumedics (Inst); Janssen (Inst); Novartis (Inst); pfizer (Inst); Zenith Epigenetics (Inst)
 
Daniel J. George
Leadership - Capio BioSciences
Honoraria - American Association for Cancer Research; AstraZeneca; Aveo; Axess Oncology; Bayer; Eisai; EMD Serono; Exelixis; IDEOlogy Health; Janssen Oncology; Medscape; Merck; Millennium Medical Publishing; Myovant Sciences; Nektar; Novartis; OncLive; Pfizer; Propella Therapeutics; Sanofi; Seagen; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Exelixis; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Myovant Sciences; Novartis; Pfizer; Physicans' Education Resource; Propella Therapeutics; RevHealth; Sanofi; Xcures
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Dendreon (Inst); Exelixis (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Expert Testimony - Exelixis
Travel, Accommodations, Expenses - Bayer; Exelixis; Novartis; Pfizer
 
Emmanuel S. Antonarakis
Honoraria - AIkido Pharma; Amgen; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Celgene (Inst); ClinicalMind; Clovis Oncology (Inst); Constellation Pharmaceuticals; Curium Pharma; Dendreon (Inst); ESSA; Exact Sciences; Foundation Medicine; GlaxoSmithKline; InVitae; ISMAR Health Care; Janssen Biotech; Lilly; Medivation; Merck; Orion; Sanofi; Tempus
Consulting or Advisory Role - AIkido Pharma; Amgen; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Clovis Oncology; Constellation Pharmaceuticals; Curium Pharma; Dendreon; ESSA; Exact Sciences; Foundation Medicine; GlaxoSmithKline; InVitae; ISMAR Health Care; Janssen Biotech; Lilly; Medivation; Merck; Orion; Sanofi; Tempus
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Celgene; Clovis Oncology; Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Daniel Costin Danila
Honoraria - Angle; Astellas Pharma; AxImmune; Cambridge Healthtech Institute; Clovis Oncology; Pfizer; Pfizer
Consulting or Advisory Role - Angle; AxImmune; BioView; Clovis Oncology; Pfizer; Sanador
Research Funding - Amgen (Inst); Biosplice (Inst); Janssen Research & Development (Inst); Prostate Cancer Foundation
Patents, Royalties, Other Intellectual Property - GENE EXPRESSION PROFILE ASSOCIATED WITH PROSTATE CANCER
 
Russell Zelig Szmulewitz
Honoraria - Astellas Pharma; Pfizer/Astellas
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Exelixis; Janssen Oncology; Merck; Novartis; Pfizer; Sanofi
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Harpoon therapeutics (Inst); Janssen Oncology (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Plexxikon (Inst); Progenics (Inst)
Patents, Royalties, Other Intellectual Property - Patent licensed by University of Chicago of which I am co-inventor to Corcept Therapeutics for combination AR/GR inhibition in prostate cancer
Travel, Accommodations, Expenses - Corcept Therapeutics
 
Donald P. McDonnell
Employment - Duke University
Stock and Other Ownership Interests - G1 Therapeutics; Rappta Therapeutics; X-RAD Therapeutics; Zentalis
Consulting or Advisory Role - Bristol-Myers Squibb; G1 therapeutics; Rappta Therapeutics; zentalis
Research Funding - Bristol-Myers Squibb; LQT Therapeutics; Novartis; Rappta Therapeutics; Ribometrix; Zentalis
Patents, Royalties, Other Intellectual Property - I am an inventor on two patents (assigned to Duke) that covers the use of Lasofoxifene for ESR1 mutant breast cancers. Licensed to Sermonix; Inventor on two patents (Assigned to Duke) licensed to Radius Health covering the use of Rad1901 for Breast cancer.
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
John D. Norris
No Relationships to Disclose
 
Changxue Lu
Patents, Royalties, Other Intellectual Property - Inventor of the patent that was licensed to Qiagen and received royalty
 
Jun Luo
Honoraria - Beijing Biote Pharmaceutical
Consulting or Advisory Role - Sun Pharma
Research Funding - Calibr (Inst); cardiff Oncology (Inst); Constellation Pharmaceuticals (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - co-inventor of a patent on a urine test pending (Inst); Jun Luo is a co-inventor of a technology assigned to Johns Hopkins University who licensed to Tokai Pharmaceuticals. (Inst); Jun Luo is a co-inventor of a technology licensed to A&G Pharmaceuticals (Inst); Jun Luo is a co-inventor of a technology licensed to Qiagen (Inst)
 
Andrew J. Armstrong
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Epic Sciences; Exelixis; FORMA Therapeutics; GoodRx; IDEAYA Biosciences; Janssen; Merck; Myovant Sciences; Novartis; Pfizer
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); FORMA Therapeutics (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc